{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["Not provided"],"condition":["Colorectal Cancer","Colorectal Neoplasms"],"disease":["Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2018726"],"location":["France"],"study_start_month":["Not provided"],"keyword":["Capecitabine"],"repository":["ECRIN MDR"],"study_status":["Not provided"],"additional_accession":[]},"is_claimable":false,"name":"Xeloda Vs Monitoring in Advanced Colorectal Cancer Responsive to Chemotherapy","description":"To compare maintenance chemotherapy with Xeloda to control after best response with first line chemotherapy in advanced colorectal cancer. Main endpoint is progression free survival. A total of 300 patients will be included.","dates":{"creation":"1900-01-01"},"accession":"2018726","cross_references":{"ClinicalTrials___gov":["NCT00189683"]}}